ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Liver Transplants Extend Survival In Early-Stage Cancer

January 27, 2006

Research Suggestions Considered By DCBD Diagnostic Group

July 11, 1980

In Brief: Schepartz To Leave NCI for Academia; Woolley Names To Head Clinical Research At Lombardi

March 9, 1984

In Brief: James Cancer Hospial Recieves $20M Donation

January 22, 1999

NCI Told To “Cut Out The Nonsense,” Adequately Fund Programs At Centers Required By Mandates

November 5, 1976

How NCI Plans to Spend the $3 Billion Budget; But First, A Caveat From the Director

November 19, 1999